Intradetrusor Onabotulinumtoxin A (Botox) with TURP or Aquablation for Mixed Lower Urinary Tract Symptoms in Men

What this Trial Is About

Researchers are studying men with longstanding obstructive lower urinary tract symptoms caused by benign prostatic hypertrophy (BPH) who may also experience symptoms of overactive bladder syndrome (OAB). This study aims to evaluate the outcomes of giving Botox medication at the same time as two standard surgical treatments for BPH: Transurethral Resection of the Prostate (TURP) and Transurethral Waterjet Ablation of the Prostate (Aquablation). Botox is approved to treat overactive bladder, and the study focuses on whether combining these treatments affects post-operative symptoms. The study involves men aged 18 or older who are scheduled for TURP or Aquablation surgery along with Botox injection into the bladder muscle. Participants will be observed to see if this combined approach reduces irritative voiding symptoms that often worsen right after surgery, such as urinary frequency and urgency. The study will monitor hospital stays and rates of urinary retention as secondary outcomes. Participants will have follow-up visits at 1 week, 4 weeks, and 12 weeks after surgery. These visits will include assessments like bladder scans, symptom questionnaires, and evaluations of urinary retention and hospital readmissions. Researchers will track patient-reported outcomes and clinical measures to understand the effects of concurrent Botox and surgery over a four-month period.

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms